Introduced Version

SENATE RESOLUTION No. ___

DIGEST OF INTRODUCED RESOLUTION

A SENATE RESOLUTION urging the Legislative Council to assign the Health Finance Commission to study the feasibility of the Family and Social Services Administration requiring all generic drug manufacturers whose products are to be provided to Medicaid recipients to compete in a competitive bidding process.

Gard

_____, read first time and referred to Committee on

First Regular Session 117th General Assembly (2011)

SENATE RESOLUTION

MADAM PRESIDENT:

I offer the following resolution and move its adoption:

A SENATE RESOLUTION urging the Legislative Council to assign the Health Finance Commission to study the feasibility of the Family and Social Services Administration requiring all generic drug manufacturers whose products are to be provided to Medicaid recipients to compete in a competitive bidding process.

Whereas, With every prescription filled with a generic drug, the consumer receives the same medicine as the brand name drug, with the same quality and same result, but at a much lower cost;

Whereas, For more than 25 years, America's generic pharmaceutical industry has been providing Food and Drug Administration (FDA) approved generic versions of brand name medicines at a savings to consumers of 30% to as much as 80%;

Whereas, Millions of Medicaid recipients nationwide are using generic drugs to treat a variety of medical conditions, including infection, heart disease, and cancer;

Whereas, Generic drugs are rigorously tested by the FDA and must prove that they are the same medicine with the same active ingredients, strengths, and dosages as their brand-name counterparts;

Whereas, There are thousands of generic drugs available today, and all are manufactured and inspected under the same strict quality guidelines as brand name drugs;

Whereas, For most brand name products there are multiple generic products available that can vary greatly in price; and

Whereas, The state Medicaid program has encouraged the use of generic drugs by Medicaid recipients, but it has not taken advantage of the savings that could be generated by taking advantage of the competition among generic drug manufacturers whose pricing of generic drugs varies greatly: Therefore,

Be it resolved by the Senate of the General Assembly of the State of Indiana:

SECTION 1. That the Legislative Council is urged to assign the Health Finance Commission to study whether the Family and Social Services Administration shall require all generic drug manufacturers whose products are to be provided to Medicaid recipients to compete in a competitive bidding process created by the agency to ensure that the agency and its agents are providing Medicaid recipients with quality generic products at a competitively bid cost.